Open access · CC-BY
via OpenAlex
Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
Girish Harinath, Virginia Lee, Andy Nyquist, Mauricio Moel, Stefanie L. Morgan, Anar Isman, Sajad Zalzala
Aging · 2025 · ▲ 47 citations
Abstract
Design: This 48-week decentralized, double-blinded, randomized, placebo-controlled trial (NCT04488601) evaluated the long-term safety of intermittent low-dose mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) in a healthy, normative-aging human cohort. Participants received placebo, 5 mg or 10 mg compounded rapamycin weekly. The primary outcome measure was visceral adiposity (by DXA scan), secondary outcomes were blood biomarkers, and lean tissue and bone mineral content (by DXA scan). Established surveys were utilized to evaluate health and well-being. Safety was assessed through adverse events and blood biomarker monitoring. Results: Adverse and serious adverse events were similar across all groups. Visceral adiposity did not change significantly (ηp2 = 0.001, p = 0.942), and changes in blood biomarkers remained within normal ranges. Lean tissue mass (ηp2 = 0.202, p = 0.013) and self-reported pain (ηp2 = 0.168, p = 0.015) improved significantly for women using 10 mg rapamycin. Self-reported emotional well-being (ηp2 = 0.108, p = 0.023) and general health (ηp2 = 0.166, p = 0.004) also improved for those using 5 mg rapamycin. No other significant effects were observed. Conclusions: Low-dose, intermittent rapamycin administration over 48 weeks is relatively safe in healthy, normative-aging adults, and was associated with significant improvements in lean tissue mass and pain in women. Future work will evaluate benefits of a broader range of rapamycin doses on healthspan(definition) metrics for longevity, and will aim to more comprehensively establish efficacy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18632/aging.206235
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Harinath, G., Lee, V., Nyquist, A., Moel, M., Morgan, S.L., Isman, A., & Zalzala, S. (2025). Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. <em>Aging</em>. https://doi.org/10.18632/aging.206235
Vancouver
Harinath G, Lee V, Nyquist A, Moel M, Morgan SL, Isman A, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging. 2025. doi:10.18632/aging.206235.
BibTeX
@article{girish2025Influe,
title = {Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results},
author = {Girish Harinath and Virginia Lee and Andy Nyquist and Mauricio Moel and Stefanie L. Morgan and Anar Isman and Sajad Zalzala},
journal = {Aging},
year = {2025},
doi = {10.18632/aging.206235},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Scientific Reports 2019
Open access · CC-BY
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION 2026
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of NVTIA® Ergothioneine Supplementation on Healthy Aging Biomarkers and Skin Health in Healthy Adults
EBioMedicine 2025
Open access · CC-BY
A pilot study of senolytics to improve cognition and mobility in older adults at risk for Alzheimer’s disease
Chong Kun Dang Pharmaceutical 2019
Open access · US-GOV
An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects
Journal of the Endocrine Society 2024
Open access · CC-BY
6711 Single Nuclei RNA-seq To Map Adipose Cellular Populations And Senescent Cells In Response To A Lifestyle Or Senolytic Intervention In Older Adults With Obesity: A Double-Blind, Placebo-Controlled, Randomized Trial
Pusan National University Yangsan Hospital 2019
Open access · US-GOV